These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 14697803)
1. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Soh CH; Oleske JM; Brady MT; Spector SA; Borkowsky W; Burchett SK; Foca MD; Handelsman E; Jiménez E; Dankner WM; Hughes MD; Lancet; 2003 Dec; 362(9401):2045-51. PubMed ID: 14697803 [TBL] [Abstract][Full Text] [Related]
2. Protease inhibitor therapy in HIV-infected children. Feingold AR; Rutstein RM; Meislich D; Brown T; Rudy BJ AIDS Patient Care STDS; 2000 Nov; 14(11):589-93. PubMed ID: 11155900 [TBL] [Abstract][Full Text] [Related]
3. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Rudin C; Burri M; Shen Y; Rode R; Nadal D; ; Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386 [TBL] [Abstract][Full Text] [Related]
4. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting. Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K; AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097 [TBL] [Abstract][Full Text] [Related]
6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
7. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769 [TBL] [Abstract][Full Text] [Related]
8. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A; Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284 [TBL] [Abstract][Full Text] [Related]
9. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356 [TBL] [Abstract][Full Text] [Related]
10. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722 [TBL] [Abstract][Full Text] [Related]
11. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ; Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704 [TBL] [Abstract][Full Text] [Related]
12. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Miller TL; Mawn BE; Orav EJ; Wilk D; Weinberg GA; Nicchitta J; Furuta L; Cutroni R; McIntosh K; Burchett SK; Gorbach SL Pediatrics; 2001 May; 107(5):E77. PubMed ID: 11331727 [TBL] [Abstract][Full Text] [Related]